A biotechnology company spun off from University of Arizona research hopes to commercialize methods to stunt blood-vessel growth in tumors. The research under a National Institutes of Health (news - web sites) grant has shown that a growth regulator called apelin is a potent stimulator of blood-vessel growth, said Paul A. Krieg, a professor who formed Angionics Inc. recently. “What we’re hoping as a startup company is that maybe by blocking the apelin, we may also block the tumor,” said Krieg, who works in the university’s department of cell biology and anatomy.
